
Generation Bio Co. GBIO
Quartalsbericht 2025-Q3
hinzugefügt 16.05.2026
Generation Bio Co. Langfristiger Schuldenstrom 2011-2026 | GBIO
Langfristiger Schuldenstrom Jährlich Generation Bio Co.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13 M | 8.12 M | 7.09 M | 4.61 M | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 13 M | 4.61 M | 8.2 M |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
103 K | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
102 K | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B | ||
|
Athira Pharma
ATHA
|
465 K | - | - | $ 269 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
773 K | - | 0.74 % | $ 768 M | ||
|
Galera Therapeutics
GRTX
|
133 K | - | -32.59 % | $ 7.61 M | ||
|
Esperion Therapeutics
ESPR
|
2.1 M | $ 3.13 | - | $ 651 M | ||
|
Eton Pharmaceuticals
ETON
|
65 K | $ 35.0 | 1.6 % | $ 942 M | ||
|
Forte Biosciences
FBRX
|
416 K | $ 22.0 | 8.32 % | $ 285 M | ||
|
Celyad Oncology SA
CYAD
|
137 K | - | - | $ 12.5 M | ||
|
Berkeley Lights
BLI
|
3.29 M | - | -7.31 % | $ 87 M | ||
|
IMV
IMV
|
320 K | - | - | $ 13.1 M | ||
|
BioNTech SE
BNTX
|
45 M | $ 90.93 | 0.63 % | $ 22 B | ||
|
Autolus Therapeutics plc
AUTL
|
4.56 M | $ 1.65 | 1.85 % | $ 439 M | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
Grifols, S.A.
GRFS
|
117 M | $ 8.11 | -0.98 % | $ 5.51 B | ||
|
Heron Therapeutics
HRTX
|
3.04 M | $ 0.87 | 3.09 % | $ 145 M | ||
|
Compugen Ltd.
CGEN
|
521 K | $ 2.61 | -3.51 % | $ 244 M | ||
|
Anika Therapeutics
ANIK
|
2.05 M | $ 15.02 | -0.79 % | $ 215 M | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M | ||
|
Incyte Corporation
INCY
|
5.7 M | $ 97.41 | 0.34 % | $ 19 B | ||
|
Ionis Pharmaceuticals
IONS
|
9.51 M | $ 75.78 | 0.96 % | $ 12.1 B | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
56 K | $ 3.44 | -0.58 % | $ 5.66 M | ||
|
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | ||
|
Coherus BioSciences
CHRS
|
1.83 M | $ 1.57 | 3.97 % | $ 184 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
4.16 M | - | - | $ 28.6 M | ||
|
Arcutis Biotherapeutics
ARQT
|
294 K | $ 21.01 | 2.64 % | $ 2.67 B | ||
|
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M |